Alpha-2'-deoxythioguanosine clinical trials
Also written THIO and 6-Thio-2'-Deoxyguanosine.
How each study uses alpha-2'-deoxythioguanosine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the alpha-2'-deoxythioguanosine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Maia Biotechnology (2) · University of Texas Southwestern Medical Center (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Antimetabolites source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test alpha-2'-deoxythioguanosine, phase 3 first.
- Jul 2027A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLCPhase 3 · Maia Biotechnology
- Sep 2027THIO Sequenced With Cemiplimab in Advanced NSCLCPhase 2 · Maia Biotechnology
Studies
Open first, then newest update. How each study uses alpha-2'-deoxythioguanosine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- THIO and Cadonilimab in Resectable Hepatocellular CarcinomaRecruitingEarly Phase 1University of Texas Southwestern Medical CenterNCT07446257Written as ateganosine
- A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLCRecruitingPhase 3Maia BiotechnologyNCT06908304Written as 6-Thio-2'-Deoxyguanosine
- THIO Sequenced With Cemiplimab in Advanced NSCLCActive, not recruitingPhase 2Maia BiotechnologyNCT05208944Written as 6-Thio-2'-Deoxyguanosine
Codes
What other systems call alpha-2'-deoxythioguanosine · ClinicalTrials.gg INT002245
- MeSH (NLM) C002062alpha-2'-deoxythioguanosineOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C002062 | alpha-2'-deoxythioguanosine | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.